Clinical Trial Update: A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A [Phase 3]

View source ↗

Summary

Phase 3 trial update for Turoctocog alfa pegol (N8-GP) in Haemophilia A completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Haemophilia

Drugs mentioned

• Turoctocog alfa pegol (Turoctocog alfa pegol)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Congenital Bleeding Disorder, Haemophilia A | Phase 3 | Status: COMPLETED | Results posted: 2021-11-26